BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January

Bristol Myers Squibb’s second CAR-T cell therapy idecabtagene vicleucel (ide-cel) cleared a key Japanese health ministry advisory committee on December 6. This opens the way for its official approval as early as January as the country’s fourth CAR-T product. Ide-cel,...read more